GB0309009D0 - Quinazoline derivatives - Google Patents

Quinazoline derivatives

Info

Publication number
GB0309009D0
GB0309009D0 GBGB0309009.9A GB0309009A GB0309009D0 GB 0309009 D0 GB0309009 D0 GB 0309009D0 GB 0309009 A GB0309009 A GB 0309009A GB 0309009 D0 GB0309009 D0 GB 0309009D0
Authority
GB
United Kingdom
Prior art keywords
quinazoline derivatives
effect
tyrxosine
quinazsoline
animnal
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
GBGB0309009.9A
Other languages
English (en)
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
AstraZeneca AB
Original Assignee
AstraZeneca AB
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by AstraZeneca AB filed Critical AstraZeneca AB
Priority to GBGB0309009.9A priority Critical patent/GB0309009D0/en
Publication of GB0309009D0 publication Critical patent/GB0309009D0/en
Priority to ES04728367T priority patent/ES2329576T3/es
Priority to PCT/GB2004/001713 priority patent/WO2004093880A1/en
Priority to CA002526897A priority patent/CA2526897A1/en
Priority to HK06107909.9A priority patent/HK1087632B/en
Priority to AT04728367T priority patent/ATE438402T1/de
Priority to KR1020057020096A priority patent/KR20060006821A/ko
Priority to EP04728367A priority patent/EP1631292B1/en
Priority to MXPA05011332A priority patent/MXPA05011332A/es
Priority to CNB2004800170469A priority patent/CN100406453C/zh
Priority to JP2006506155A priority patent/JP2006524218A/ja
Priority to DE602004022404T priority patent/DE602004022404D1/de
Priority to AU2004231349A priority patent/AU2004231349A1/en
Priority to NZ543015A priority patent/NZ543015A/en
Priority to BRPI0409633-9A priority patent/BRPI0409633A/pt
Priority to US10/554,202 priority patent/US20070149546A1/en
Priority to ZA200508525A priority patent/ZA200508525B/en
Priority to NO20054856A priority patent/NO20054856L/no
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/70—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings condensed with carbocyclic rings or ring systems
    • C07D239/72—Quinazolines; Hydrogenated quinazolines
    • C07D239/86—Quinazolines; Hydrogenated quinazolines with hetero atoms directly attached in position 4
    • C07D239/94—Nitrogen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Medicines Containing Plant Substances (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
GBGB0309009.9A 2003-04-22 2003-04-22 Quinazoline derivatives Ceased GB0309009D0 (en)

Priority Applications (18)

Application Number Priority Date Filing Date Title
GBGB0309009.9A GB0309009D0 (en) 2003-04-22 2003-04-22 Quinazoline derivatives
US10/554,202 US20070149546A1 (en) 2003-04-22 2004-04-20 4-Anilino-quinazoline derivatives as antiproliferative agents
MXPA05011332A MXPA05011332A (es) 2003-04-22 2004-04-20 Derivados de 4-anilino-quinazolina como agentes antiproliferativos.
JP2006506155A JP2006524218A (ja) 2003-04-22 2004-04-20 増殖抑制薬としての４−アニリノキナゾリン誘導体
CA002526897A CA2526897A1 (en) 2003-04-22 2004-04-20 4-anilino-quinazoline derivatives as antiproliferative agents
HK06107909.9A HK1087632B (en) 2003-04-22 2004-04-20 4-anilino-quinazoline derivatives as antiproliferative agents
AT04728367T ATE438402T1 (de) 2003-04-22 2004-04-20 4-anilino-chinazolin-derivate als proliferationshemmende mittel
KR1020057020096A KR20060006821A (ko) 2003-04-22 2004-04-20 항증식제로서의 4-아닐리노-퀴나졸린 유도체
EP04728367A EP1631292B1 (en) 2003-04-22 2004-04-20 4-anilino-quinazoline derivatives as antiproliferative agents
ES04728367T ES2329576T3 (es) 2003-04-22 2004-04-20 Derivados de 4-anilino-quinazolina como agentes antiproliferativos.
CNB2004800170469A CN100406453C (zh) 2003-04-22 2004-04-20 抗增殖药4-苯胺基-喹唑啉衍生物
PCT/GB2004/001713 WO2004093880A1 (en) 2003-04-22 2004-04-20 4-anilino-quinazoline derivatives as antiproliferative agents
DE602004022404T DE602004022404D1 (de) 2003-04-22 2004-04-20 4-anilino-chinazolin-derivate als proliferationshemmende mittel
AU2004231349A AU2004231349A1 (en) 2003-04-22 2004-04-20 4-anilino-quinazoline derivatives as antiproliferative agents
NZ543015A NZ543015A (en) 2003-04-22 2004-04-20 4-Anilino-quinazoline derivatives for producing antiproliferative effect by inhibiting erbB2 receptor tyrosine kinase
BRPI0409633-9A BRPI0409633A (pt) 2003-04-22 2004-04-20 derivado de quinazolina, composição farmacêutica, e processo para a preparação do derivado de quinazolina
NO20054856A NO20054856L (no) 2003-04-22 2005-10-20 4-anilino-kinazolinderivater som antiproliferative midler
ZA200508525A ZA200508525B (en) 2003-04-22 2005-10-20 4-Anilino-quinazoline derivatives as antiproliferative agents

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GBGB0309009.9A GB0309009D0 (en) 2003-04-22 2003-04-22 Quinazoline derivatives

Publications (1)

Publication Number Publication Date
GB0309009D0 true GB0309009D0 (en) 2003-05-28

Family

ID=9957022

Family Applications (1)

Application Number Title Priority Date Filing Date
GBGB0309009.9A Ceased GB0309009D0 (en) 2003-04-22 2003-04-22 Quinazoline derivatives

Country Status (17)

Country Link
US (1) US20070149546A1 (enExample)
EP (1) EP1631292B1 (enExample)
JP (1) JP2006524218A (enExample)
KR (1) KR20060006821A (enExample)
CN (1) CN100406453C (enExample)
AT (1) ATE438402T1 (enExample)
AU (1) AU2004231349A1 (enExample)
BR (1) BRPI0409633A (enExample)
CA (1) CA2526897A1 (enExample)
DE (1) DE602004022404D1 (enExample)
ES (1) ES2329576T3 (enExample)
GB (1) GB0309009D0 (enExample)
MX (1) MXPA05011332A (enExample)
NO (1) NO20054856L (enExample)
NZ (1) NZ543015A (enExample)
WO (1) WO2004093880A1 (enExample)
ZA (1) ZA200508525B (enExample)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN115260164A (zh) * 2021-05-01 2022-11-01 杭州星鳌生物科技有限公司 新型4(3h)-喹唑啉酮类似物的制备方法、结构组成及其在抗肿瘤药物中的应用

Families Citing this family (35)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2005515176A (ja) * 2001-11-03 2005-05-26 アストラゼネカ アクチボラグ 抗腫瘍剤としてのキナゾリン誘導体
GB0126433D0 (en) * 2001-11-03 2002-01-02 Astrazeneca Ab Compounds
US6924285B2 (en) 2002-03-30 2005-08-02 Boehringer Ingelheim Pharma Gmbh & Co. Bicyclic heterocyclic compounds, pharmaceutical compositions containing these compounds, their use and process for preparing them
US20070021429A1 (en) * 2003-04-09 2007-01-25 Yves St-Denis Condensed n-heterocyclic compounds and their use as crf receptor antagonists
GB0309850D0 (en) * 2003-04-30 2003-06-04 Astrazeneca Ab Quinazoline derivatives
WO2004106308A1 (en) * 2003-05-27 2004-12-09 Pfizer Products Inc. Quinazolines and pyrido [3,4-d] pyrimidines as receptor tyrosine kinase inhibitors
US7569577B2 (en) * 2003-09-16 2009-08-04 Astrazeneca Ab Quinazoline derivatives as tyrosine kinase inhibitors
GB0321648D0 (en) * 2003-09-16 2003-10-15 Astrazeneca Ab Quinazoline derivatives
EP1664030A1 (en) * 2003-09-16 2006-06-07 AstraZeneca AB Quinazoline derivatives
AU2004272350A1 (en) * 2003-09-16 2005-03-24 Astrazeneca Ab Quinazoline derivatives as tyrosine kinase inhibitors
BRPI0414488A (pt) * 2003-09-16 2006-11-14 Astrazeneca Ab derivado de quinazolina, composição farmacêutica, uso de um derivado de quinazolina, métodos para produzir um efeito anti - proliferativo em um animal de sangue quente, para prevenção ou tratamento de tumores em um aminal de sangue quente, para fornecer um efeito inibidor da tirosina quinase de egfr seletivo em um animal de sangue quente e para tratar um cáncer em um animal de sangue quente e, processo para a preparação de um derivado de quinazolina
GB0322409D0 (en) 2003-09-25 2003-10-29 Astrazeneca Ab Quinazoline derivatives
GB0326459D0 (en) 2003-11-13 2003-12-17 Astrazeneca Ab Quinazoline derivatives
ATE413389T1 (de) * 2004-02-03 2008-11-15 Astrazeneca Ab Chinazolinderivate
CA2567832A1 (en) * 2004-06-04 2005-12-15 Astrazeneca Ab Quinazoline derivatives as erbb receptor tyrosine kinases
CN101124228B (zh) * 2004-12-14 2011-06-15 阿斯利康(瑞典)有限公司 用作抗肿瘤药物的吡唑并嘧啶化合物
GB0427917D0 (en) * 2004-12-21 2005-01-26 Astrazeneca Ab Chemical compounds
GB0504474D0 (en) * 2005-03-04 2005-04-13 Astrazeneca Ab Chemical compounds
GB0508717D0 (en) * 2005-04-29 2005-06-08 Astrazeneca Ab Chemical compounds
GB0508715D0 (en) * 2005-04-29 2005-06-08 Astrazeneca Ab Chemical compounds
US7820683B2 (en) * 2005-09-20 2010-10-26 Astrazeneca Ab 4-(1H-indazol-5-yl-amino)-quinazoline compounds as erbB receptor tyrosine kinase inhibitors for the treatment of cancer
US20090239861A1 (en) * 2005-09-20 2009-09-24 Robert Hugh Bradbury Quinazoline derivatives as anticancer agents
WO2007063291A1 (en) * 2005-12-02 2007-06-07 Astrazeneca Ab 4-anilino-substituted quinazoline derivatives as tyrosine kinase inhibitors
ATE443053T1 (de) * 2005-12-02 2009-10-15 Astrazeneca Ab Als inhibitoren von erbb-tyrosinkinase verwendete chinazoleinderivate
US7547781B2 (en) 2006-09-11 2009-06-16 Curis, Inc. Quinazoline based EGFR inhibitors containing a zinc binding moiety
BRPI0715016A2 (pt) 2006-09-11 2013-05-28 Curis Inc composiÇço, composiÇço farmacÊutica, mÉtodo para tratar uma doenÇa ou distérbio relacionada com tirosina quinase de egfr em um individuo necessitando o mesmo, mÉtodo para tratar uma doenÇa mediada por hdac e mÉtodo para tratar doenÇas medidas tanto por tirosina quinase de egfr quanto hdac
WO2008041118A2 (en) * 2006-10-04 2008-04-10 Pfizer Products Inc. Pyrido[4,3-d]pyrimidin-4(3h)-one derivatives as calcium receptor antagonists
EP1921070A1 (de) 2006-11-10 2008-05-14 Boehringer Ingelheim Pharma GmbH & Co. KG Bicyclische Heterocyclen, diese Verbindungen enthaltende Arzneimittel, deren Verwendung und Verfahren zu ihrer Herstelllung
EA200901041A1 (ru) 2007-02-06 2010-02-26 Бёрингер Ингельхайм Интернациональ Гмбх Бициклические гетероциклы, содержащие эти соединения лекарственные средства, их применение и способ их получения
TWI377944B (en) * 2007-06-05 2012-12-01 Hanmi Holdings Co Ltd Novel amide derivative for inhibiting the growth of cancer cells
NZ585357A (en) 2007-10-29 2012-02-24 Natco Pharma Ltd Novel 4-(tetrazol-5-yl)-quinazoline derivatives as anti cancer agents
RS52573B (sr) 2008-02-07 2013-04-30 Boehringer Ingelheim International Gmbh Spirociklični heterocikli, lekovi koji sadrže navedeno jedinjenje, njihova primena i postupak za njihovu proizvodnju
BRPI0912170A2 (pt) 2008-05-13 2015-10-13 Astrazeneca Ab composto, forma a, processo para a preparação da mesma, composição farmacêutica, uso de um composto, e, método para tratar um câncer em um animal de sangue quente
CA2733153C (en) 2008-08-08 2016-11-08 Boehringer Ingelheim International Gmbh Cyclohexyloxy substituted heterocycles, pharmaceutical compositions containing these compounds and processes for preparing them
CA2746650A1 (en) * 2008-12-11 2010-06-17 Proteus Biomedical, Inc. Evaluation of gastrointestinal function using portable electroviscerography systems and methods of using the same

Family Cites Families (41)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS5538325A (en) * 1978-09-11 1980-03-17 Sankyo Co Ltd 4-anilinoquinazoline derivative and its preparation
US4335127A (en) * 1979-01-08 1982-06-15 Janssen Pharmaceutica, N.V. Piperidinylalkyl quinazoline compounds, composition and method of use
GB2160201B (en) * 1984-06-14 1988-05-11 Wyeth John & Brother Ltd Quinazoline and cinnoline derivatives
US4921863A (en) * 1988-02-17 1990-05-01 Eisai Co., Ltd. Cyclic amine derivatives
CA1340821C (en) * 1988-10-06 1999-11-16 Nobuyuki Fukazawa Heterocyclic compounds and anticancer-drug reinforcing agents containing them as effective components
US5721237A (en) * 1991-05-10 1998-02-24 Rhone-Poulenc Rorer Pharmaceuticals Inc. Protein tyrosine kinase aryl and heteroaryl quinazoline compounds having selective inhibition of HER-2 autophosphorylation properties
TW321649B (enExample) * 1994-11-12 1997-12-01 Zeneca Ltd
US5747498A (en) * 1996-05-28 1998-05-05 Pfizer Inc. Alkynyl and azido-substituted 4-anilinoquinazolines
US6046206A (en) * 1995-06-07 2000-04-04 Cell Pathways, Inc. Method of treating a patient having a precancerous lesions with amide quinazoline derivatives
GB9514265D0 (en) * 1995-07-13 1995-09-13 Wellcome Found Hetrocyclic compounds
GB9624482D0 (en) * 1995-12-18 1997-01-15 Zeneca Phaema S A Chemical compounds
CA2216169C (en) * 1996-01-31 2007-01-23 Gist-Brocades B.V. Use of compositions comprising stabilized biologically effective compounds
GB9603095D0 (en) * 1996-02-14 1996-04-10 Zeneca Ltd Quinazoline derivatives
US6004967A (en) * 1996-09-13 1999-12-21 Sugen, Inc. Psoriasis treatment with quinazoline compounds
DE19651439A1 (de) * 1996-12-11 1998-06-18 Hoechst Ag Polymerisierbare Biaryle, Verfahren zur Herstellung und deren Verwendung
US5929080A (en) * 1997-05-06 1999-07-27 American Cyanamid Company Method of treating polycystic kidney disease
US6384223B1 (en) * 1998-07-30 2002-05-07 American Home Products Corporation Substituted quinazoline derivatives
US6297258B1 (en) * 1998-09-29 2001-10-02 American Cyanamid Company Substituted 3-cyanoquinolines
UA71945C2 (en) * 1999-01-27 2005-01-17 Pfizer Prod Inc Substituted bicyclic derivatives being used as anticancer agents
AU3281600A (en) * 1999-02-27 2000-09-21 Boehringer Ingelheim Pharma Gmbh & Co. Kg 4-amino-quinazoline and quinoline derivatives having an inhibitory effect on signal transsduction mediated by tyrosine kinases
US6080747A (en) * 1999-03-05 2000-06-27 Hughes Institute JAK-3 inhibitors for treating allergic disorders
US20020082270A1 (en) * 2000-08-26 2002-06-27 Frank Himmelsbach Aminoquinazolines which inhibit signal transduction mediated by tyrosine kinases
US6562319B2 (en) * 2001-03-12 2003-05-13 Yissum Research Development Company Of The Hebrew University Of Jerusalem Radiolabeled irreversible inhibitors of epidermal growth factor receptor tyrosine kinase and their use in radioimaging and radiotherapy
WO2002094790A1 (en) * 2001-05-23 2002-11-28 Mitsubishi Pharma Corporation Fused heterocyclic compound and medicinal use thereof
JP2005515176A (ja) * 2001-11-03 2005-05-26 アストラゼネカ アクチボラグ 抗腫瘍剤としてのキナゾリン誘導体
GB0126433D0 (en) * 2001-11-03 2002-01-02 Astrazeneca Ab Compounds
TWI324597B (en) * 2002-03-28 2010-05-11 Astrazeneca Ab Quinazoline derivatives
US6924285B2 (en) * 2002-03-30 2005-08-02 Boehringer Ingelheim Pharma Gmbh & Co. Bicyclic heterocyclic compounds, pharmaceutical compositions containing these compounds, their use and process for preparing them
GB0309850D0 (en) * 2003-04-30 2003-06-04 Astrazeneca Ab Quinazoline derivatives
GB0317665D0 (en) * 2003-07-29 2003-09-03 Astrazeneca Ab Qinazoline derivatives
BRPI0413066A (pt) * 2003-07-29 2006-10-17 Astrazeneca Ab derivado de quinazolina, ou um sal farmaceuticamente aceitável, ou um éster farmaceuticamente aceitável do mesmo, da fórmula i, uso e processo para a preparação do mesmo, composto, composição farmacêutica, e, métodos para a produção de um efeito antiproliferativo em um animal de sangue quente, para a prevenção ou tratamento de um tumor, para prover um efeito inibitório de tirosina quinase de egfr seletivo, e para tratar um cáncer em um animal de sangue quente
BRPI0414488A (pt) * 2003-09-16 2006-11-14 Astrazeneca Ab derivado de quinazolina, composição farmacêutica, uso de um derivado de quinazolina, métodos para produzir um efeito anti - proliferativo em um animal de sangue quente, para prevenção ou tratamento de tumores em um aminal de sangue quente, para fornecer um efeito inibidor da tirosina quinase de egfr seletivo em um animal de sangue quente e para tratar um cáncer em um animal de sangue quente e, processo para a preparação de um derivado de quinazolina
AU2004272350A1 (en) * 2003-09-16 2005-03-24 Astrazeneca Ab Quinazoline derivatives as tyrosine kinase inhibitors
US7569577B2 (en) * 2003-09-16 2009-08-04 Astrazeneca Ab Quinazoline derivatives as tyrosine kinase inhibitors
GB0321648D0 (en) * 2003-09-16 2003-10-15 Astrazeneca Ab Quinazoline derivatives
DE602004004811T2 (de) * 2003-09-19 2007-11-22 Astrazeneca Ab Chinazolinderivate
US20070043010A1 (en) * 2003-09-25 2007-02-22 Astrazeneca Uk Limited Quinazoline derivatives
GB0322409D0 (en) * 2003-09-25 2003-10-29 Astrazeneca Ab Quinazoline derivatives
GB0326459D0 (en) * 2003-11-13 2003-12-17 Astrazeneca Ab Quinazoline derivatives
ATE413389T1 (de) * 2004-02-03 2008-11-15 Astrazeneca Ab Chinazolinderivate
CA2567832A1 (en) * 2004-06-04 2005-12-15 Astrazeneca Ab Quinazoline derivatives as erbb receptor tyrosine kinases

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN115260164A (zh) * 2021-05-01 2022-11-01 杭州星鳌生物科技有限公司 新型4(3h)-喹唑啉酮类似物的制备方法、结构组成及其在抗肿瘤药物中的应用
CN115260164B (zh) * 2021-05-01 2024-03-26 杭州星鳌生物科技有限公司 新型4(3h)-喹唑啉酮类似物的制备方法、结构组成及其在抗肿瘤药物中的应用

Also Published As

Publication number Publication date
CN100406453C (zh) 2008-07-30
ES2329576T3 (es) 2009-11-27
KR20060006821A (ko) 2006-01-19
ATE438402T1 (de) 2009-08-15
HK1087632A1 (en) 2006-10-20
AU2004231349A1 (en) 2004-11-04
CA2526897A1 (en) 2004-11-04
EP1631292B1 (en) 2009-08-05
JP2006524218A (ja) 2006-10-26
NO20054856D0 (no) 2005-10-20
ZA200508525B (en) 2007-04-25
DE602004022404D1 (de) 2009-09-17
NO20054856L (no) 2005-11-21
BRPI0409633A (pt) 2006-04-25
NZ543015A (en) 2008-01-31
MXPA05011332A (es) 2005-11-28
US20070149546A1 (en) 2007-06-28
EP1631292A1 (en) 2006-03-08
WO2004093880A1 (en) 2004-11-04
CN1809360A (zh) 2006-07-26

Similar Documents

Publication Publication Date Title
GB0309009D0 (en) Quinazoline derivatives
MX2009010595A (es) Derivados de pirrolopirimidina.
NO20061320L (no) Kinazolinderivater som antitumor agenter
MX2009007302A (es) Derivados de purina.
NO20061321L (no) Kinazolinderivater som tyrosin kinase inhibitorer
MX2009009774A (es) Derivados de quinolina como fungicidas.
TN2010000101A1 (en) Fungicidal 2-alkylthio-2-quinolinyloxy -acetamide derivatives
WO2008087933A1 (ja) ＩκＢキナーゼβ阻害活性を有する新規インドール誘導体
SG170739A1 (en) Iap bir domain binding compounds
MX2009011199A (es) Derivados de pirimidina.
MEP0508A (xx) Derivati pirimidina
MX2009002229A (es) Benzotriazoles como moduladores de cinasas.
TW200800956A (en) 2-Aminopyrimidine derivatives
TW200728277A (en) Bicyclic derivatives as P38 inhibitors
UA101963C2 (en) 4-amino-pyrimidine derivatives
IL194057A0 (en) Pyrimidine, quinazoline, pteridine and triazine derivatives
UY28610A1 (es) Derivados de quinazolina
GB0508717D0 (en) Chemical compounds
MXPA05013149A (es) Derivados de imidazol como antagonistas del receptor de glutamato.
TW200607805A (en) Novel pyridazinone derivatives, methods for producing them and their use as pharmaceuticals
GB0508715D0 (en) Chemical compounds
EP1838712B8 (en) Pyrazolopyrimidine compounds as antitumor agents
TW200745090A (en) Chemical compounds
IL186034A0 (en) Pyrimidine derivatives for use as anticancer agents
DE602006009304D1 (de) Chinazoleinderivate

Legal Events

Date Code Title Description
AT Applications terminated before publication under section 16(1)